Literature DB >> 7584672

Spontaneous release of interleukin-6 by primary cultures of lymphoid and tumor cell populations purified from human ovarian carcinoma.

R A Burger1, E A Grosen, G R Ioli, M E Van Eden, M Park, M L Berman, A Manetta, P J Disaia, G A Granger, T Gatanaga.   

Abstract

Interleukin-6 (IL-6) is a cytokine that has been implicated as a growth factor in human ovarian carcinoma, yet the in vivo source of IL-6 in patients remains undefined. We measured IL-6 by ELISA in cell-free ascites (CFA) of 19 patients with ovarian carcinoma. IL-6 was detectable in all samples (mean level 3.3 ng/ml). To identify the cellular source of IL-6, we measured this cytokine by ELISA in 24-48 h supernatants of cultured lymphocyte-, macrophage-, and tumor cell-enriched populations purified from three solid ovarian carcinomas by centrifugal elutriation. All cell populations spontaneously released IL-6; however, tumor cells and tumor-associated macrophage released levels of IL-6 that greatly exceeded those released by tumor-associated lymphocytes. Kinetic studies revealed that IL-6 was detectable at 6 h and that levels increased in all cultures examined over a 48 h time course. These data suggest that both tumor and infiltrating host cells may be the source of the high levels of IL-6 found in carcinomatous ascites. Furthermore, although all three cell types examined may contribute to IL-6 production in patients with ovarian carcinoma, tumor cells are perhaps the most clinically significant source.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7584672     DOI: 10.1089/jir.1995.15.255

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  5 in total

Review 1.  Pre-treatment effects of peripheral tumors on brain and behavior: neuroinflammatory mechanisms in humans and rodents.

Authors:  Andrew Schrepf; Susan K Lutgendorf; Leah M Pyter
Journal:  Brain Behav Immun       Date:  2015-05-06       Impact factor: 7.217

2.  Sleep disturbance, cytokines, and fatigue in women with ovarian cancer.

Authors:  Lauren Clevenger; Andrew Schrepf; Desire Christensen; Koen DeGeest; David Bender; Amina Ahmed; Michael J Goodheart; Frank Penedo; David M Lubaroff; Anil K Sood; Susan K Lutgendorf
Journal:  Brain Behav Immun       Date:  2012-04-21       Impact factor: 7.217

3.  Interleukin-6, cortisol, and depressive symptoms in ovarian cancer patients.

Authors:  Susan K Lutgendorf; Aliza Z Weinrib; Frank Penedo; Daniel Russell; Koen DeGeest; Erin S Costanzo; Patrick J Henderson; Sandra E Sephton; Nicolas Rohleder; Joseph A Lucci; Steven Cole; Anil K Sood; David M Lubaroff
Journal:  J Clin Oncol       Date:  2008-09-08       Impact factor: 44.544

4.  Effects of ulinastatin and docataxel on breast tumor growth and expression of IL-6, IL-8, and TNF-α.

Authors:  Xiaoliang Zhao; Xin Sun; Feng Gao; Jie Luo; Zhijun Sun
Journal:  J Exp Clin Cancer Res       Date:  2011-02-23

5.  Diurnal cortisol and survival in epithelial ovarian cancer.

Authors:  Andrew Schrepf; Premal H Thaker; Michael J Goodheart; David Bender; George M Slavich; Laila Dahmoush; Frank Penedo; Koen DeGeest; Luis Mendez; David M Lubaroff; Steven W Cole; Anil K Sood; Susan K Lutgendorf
Journal:  Psychoneuroendocrinology       Date:  2015-01-20       Impact factor: 4.905

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.